{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:34Z","timestamp":1793643334996,"version":"4.5.1"},"reference-count":14,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T00:00:00Z","timestamp":1391385600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0087379","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T21:56:59Z","timestamp":1391464619000},"page":"e87379","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":78,"title":["Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00476996","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00406419","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00485589","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00673920","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Paul","family":"Emery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P.","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Olech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Travers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fisheleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,2,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"T D\u00f6rner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1010","article-title":"Roles of B cells in rheumatoid arthritis","volume":"5","author":"GJ Silverman","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"SB Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"JC Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"P Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biologic naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab&apos;s Efficacy in MTX iNadequate rEsponders (SERENE))","volume":"69","author":"P Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR)","volume":"49","author":"A Rubbert-Roth","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"RF van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Emery P, Bingham CO III, Keystone E, Fleischmann R, <etal>et al<\/etal>.. (2012) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients. Ann Rheum Dis [Epub ahead of print].","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/art.33317","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"W Rigby","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/art.33353","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"PP Tak","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial","volume":"71","author":"W Stohl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2217\/ijr.11.55","article-title":"Single versus dual infusion of B cell depleting antibody ocrelizumab (humanized aCD20) in rheumatoid arthritis: Results from the Phase III FEATURE trial","volume":"6","author":"JE Huffstutter","year":"2011","journal-title":"Int J Clin Rheumatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"L Kappos","year":"2011","journal-title":"Lancet"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0087379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:16:09Z","timestamp":1589012169000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0087379"}},"subtitle":[],"editor":[{"given":"C. Mary","family":"Schooling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,3]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0087379","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,3]]}}}